Literature DB >> 1975039

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

M Heim1, U A Meyer.   

Abstract

A method for genotyping poor metabolisers of debrisoquine is based on specific polymerase chain reaction (PCR) amplification of parts of mutant genes for hepatic cytochrome P450IID6. Analysis by restriction fragment length polymorphism allowed identification of only 25% of poor metabolisers, but when it was combined with allele-specific PCR over 95% of poor metabolisers could be identified. The PCR method also allowed the identification of heterozygous carriers of mutant alleles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975039     DOI: 10.1016/0140-6736(90)92086-w

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  84 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 3.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

4.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

5.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

6.  Detection of single base differences using biotinylated nucleotides with very long linker arms.

Authors:  K J Livak; F W Hobbs; R J Zagursky
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

Review 7.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

8.  Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.

Authors:  T Graf; F Broly; F Hoffmann; M Probst; U A Meyer; H Howald
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

Authors:  Norio Yasui-Furukori; Kazuo Mihara; Takenori Takahata; Akihito Suzuki; Taku Nakagami; Ronald De Vries; Tomonori Tateishi; Tsuyoshi Kondo; Sunao Kaneko
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.